Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy

被引:1
作者
Lin, Qianyi [1 ]
Chen, Dexiong [1 ]
Li, Kangde [1 ]
Fan, Xiaomin [2 ]
Cai, Qi [1 ]
Lin, Weihong [1 ]
Qin, Chunhong [1 ]
He, Tao [1 ]
机构
[1] Guangdong Med Univ, Zhanjiang Cent Hosp, Dept Liver Surg, Zhanjiang, Peoples R China
[2] Guangdong Med Univ, Zhanjiang Cent Hosp, Dept Pathol, Zhanjiang, Peoples R China
来源
FRONTIERS IN RADIOLOGY | 2022年 / 2卷
关键词
hepatocellular carcinoma; portal vein embolization (PVE); hepatic artery infusion chemotherapy; tyrosine kinase inhibitor (TKI); programmed cell death-1 inhibitor; case report;
D O I
10.3389/fradi.2022.858963
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A high proportion of massive patients with hepatocellular carcinoma (HCC) are not amenable for surgical resection at initial diagnosis, owing to insufficient future liver remnant (FLR) or an inadequate surgical margin. For such patients, portal vein embolization (PVE) is an essential approach to allow liver hypertrophy and prepare for subsequent surgery. However, the conversion resection rate of PVE only is unsatisfactory because of tumor progression while awaiting liver hypertrophy. We report here a successfully treated case of primary massive HCC, where surgical resection was completed after PVE and multimodality therapy, comprising hepatic artery infusion chemotherapy (HAIC), Lenvatinib plus Sintilimab. A pathologic complete response was achieved. This case demonstrates for the first time that combined PVE with multimodality therapy appears to be safe and effective for massive, potentially resectable HCC and can produce deep pathological remission in a primary tumor.
引用
收藏
页数:6
相关论文
共 22 条
[11]   Three Hundred and One Consecutive Extended Right Hepatectomies Evaluation of Outcome Based on Systematic Liver Volumetry [J].
Kishi, Yoji ;
Abdalla, Eddie K. ;
Chun, Yun Shin ;
Zorzi, Daria ;
Madoff, David C. ;
Wallace, Michael J. ;
Curley, Steven A. ;
Vauthey, Jean-Nicolas .
ANNALS OF SURGERY, 2009, 250 (04) :540-548
[12]   Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma [J].
Mei, Jie ;
Tang, Yu-Hao ;
Wei, Wei ;
Shi, Ming ;
Zheng, Lie ;
Li, Shao-Hua ;
Guo, Rong-Ping .
FRONTIERS IN ONCOLOGY, 2021, 11
[13]   Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study [J].
Park, Joong-Won ;
Chen, Minshan ;
Colombo, Massimo ;
Roberts, Lewis R. ;
Schwartz, Myron ;
Chen, Pei-Jer ;
Kudo, Masatoshi ;
Johnson, Philip ;
Wagner, Samuel ;
Orsini, Lucinda S. ;
Sherman, Morris .
LIVER INTERNATIONAL, 2015, 35 (09) :2155-2166
[14]   Portal vein embolization: Present and future [J].
Piron, Lauranne ;
Deshayes, Emmanuel ;
Escal, Laure ;
Souche, Regis ;
Herrero, Astrid ;
Pierredon-Foulongne, Marie-Ange ;
Assenat, Eric ;
Ngo le Lam ;
Quenet, Francois ;
Guiu, Boris .
BULLETIN DU CANCER, 2017, 104 (05) :407-416
[15]   Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview [J].
Sun, Hui-Chuan ;
Zhu, Xiao-Dong .
FRONTIERS IN ONCOLOGY, 2021, 11
[16]   Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018) [J].
Vogel, A. ;
Cervantes, A. ;
Chau, I. ;
Daniele, B. ;
Llovet, J. M. ;
Meyer, T. ;
Nault, J. -C. ;
Neumann, U. ;
Ricke, J. ;
Sangro, B. ;
Schirmacher, P. ;
Verslype, C. ;
Zech, C. J. ;
Arnold, D. ;
Martinelli, E. .
ANNALS OF ONCOLOGY, 2019, 30 (05) :871-873
[17]   Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response [J].
Yang, Keungmo ;
Sung, Pil S. ;
You, Young K. ;
Kim, Dong G. ;
Oh, Jung S. ;
Chun, Ho J. ;
Jang, Jeong W. ;
Bae, Si H. ;
Choi, Jong Y. ;
Yoon, Seung K. .
HPB, 2019, 21 (12) :1718-1726
[18]   Sequential Transcatheter Arterial Chemoembolization and Portal Vein Embolization versus Portal Vein Embolization Only before Major Hepatectomy for Patients with Hepatocellular Carcinoma [J].
Yoo, Hyunkyung ;
Kim, Jin Hyoung ;
Ko, Gi-Young ;
Kim, Kyoung Won ;
Gwon, Dong Il ;
Lee, Sung-Gyu ;
Hwang, Shin .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (05) :1251-1257
[19]   Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study [J].
Zhang, Jinliang ;
Zhang, Xihao ;
Mu, Han ;
Yu, Ge ;
Xing, Wenge ;
Wang, Lu ;
Zhang, Ti .
FRONTIERS IN ONCOLOGY, 2021, 11
[20]   Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients [J].
Zhang, Wenwen ;
Hu, Bingyang ;
Han, Jun ;
Wang, Zhanbo ;
Ma, Guangyu ;
Ye, Huiyi ;
Yuan, Jing ;
Cao, Junning ;
Zhang, Ze ;
Shi, Jihang ;
Chen, Mingyi ;
Wang, Xun ;
Xu, Yinzhe ;
Cheng, Yanshuang ;
Tian, Lantian ;
Wang, Hongguang ;
Lu, Shichun .
FRONTIERS IN ONCOLOGY, 2021, 11